Drug Transport Across the Blood-Testis and Blood-Epididymal Barriers (R61/R33 - Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this funding opportunity announcement (FOA) is to support in vivo research to elucidate the chemical features of non-native molecules that facilitate passage across the blood-testis and/or blood-epidydimal barriers.


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • Application Due Date(s): November 27, 2018, November 27, 2019, November 27, 2020

​PAR-18-853 Expiration Date November 28, 2020

Agency Website

Amount Description

The scope of the proposed project should determine the project period. The maximum period of the combined R61 and R33 phases is 5 years, with up to 2 years for the R61 phase and up to 3 years for the R33 phase. Applications with a project period less than 5 years are encouraged where feasible. 

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science

External Deadline

November 27, 2020